MAPT and neurodegenerative disease: However, it should be noted that our data are not equipped to discriminate between mild cognitive impairment due to Alzheimer’s disease/neurodegenerative disease versus stable mild cognitive impairment, which can be substantiated by CSF Aβ42, p-tau, and T-tau biomarkers [78, 79].